High expression of monocarboxylate transporter 4 (MCT 4), but not MCT 1, predicts poor prognosis in patients with non-small cell lung cancer

doi:10.21037/tcr-20-3117

HFCAS OpenIR

	High expression of monocarboxylate transporter 4 (MCT 4), but not MCT 1, predicts poor prognosis in patients with non-small cell lung cancer
	Tong, Ying-Hui 1; Hu, Xiao-Ping 2; Xiang, Xue-Ping 3; Fang, Luo 1
	2021-03-01
发表期刊	TRANSLATIONAL CANCER RESEARCH
ISSN	2218-676X
通讯作者	Xiang, Xue-Ping(xiangxueping@zju.edu.cn) ; Fang, Luo(Fangluo@zjcc.org.cn)
摘要	Background: The monocarboxylate transporter (MCT) family especially MCT1 and MCT4 have been recognized to play an important role in lactate transport, a key glycolytic product. The expression of MCT1 and MCT4 expression was previously found to be related to poor outcome in various cancer types. In this study, we investigated the expression status of MCT1 and MCT4 and their relationship with prognosis in non-small cell lung cancer (NSCLC). Methods: Expression of MCT4 and MCT1 in NSCLC tumor and adjacent lung tissues were detected by immunohistochemistry. Kaplan-Meier plots were used to evaluate two proteins' prognostic role, and the logrank test obtained the P value. For multivariate analysis, the Cox proportional-hazards regression method was performed. Results: High MCT4 and MCT1 expression was observed in cancer cells, with a rate of 45% for MCT4 versus 15% for MCT1 among all NSCLC patients. High expression of MCT4, and not MCT1, was associated with worse overall survival (OS) [hazard ratio (HR) =1.96 (1.06-3.75), P=0.032] and progressionfree survival (PFS) [HR =1.72 (1.05-2.93), P=0.032] in NSCLC patients. In our multivariate analysis, advanced cancer stage and high MCT4 level were identified as independent predictive indicators for both PFS [HR(MCT4) =1.888 (1.114-3.199), P=0.018 and OS [HR (MCT4) =2.421 (1.271-4.610), P=0.007]. Subgroup and interaction analyses were also performed in different clinical characteristic groups and no significant differences were observed. Conclusions: High MCT4 expression is a predictive marker for worse outcome in NSCLC patients.
关键词	Monocarboxylate transporter 1 (MCT1) monocarboxylate transporter 4 (MCT4) prognosis non-small cell lung cancer (NSCLC)
DOI	10.21037/tcr-20-3117
收录类别	SCI
语种	英语
资助项目	National Natural Science Foundation of China[81803549] ; Natural Science Foundation of Zhejiang Province[LQ18H310002] ; Projects of Medical and Health Technology Program in Zhejiang Province[2018253186] ; Projects of Medical and Health Technology Program in Zhejiang Province[2015KYB061]
项目资助者	National Natural Science Foundation of China ; Natural Science Foundation of Zhejiang Province ; Projects of Medical and Health Technology Program in Zhejiang Province
WOS研究方向	Oncology
WOS类目	Oncology
WOS记录号	WOS:000635021300014
出版者	AME PUBL CO
引用统计	被引频次：9[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/121595
专题	中国科学院合肥物质科学研究院
通讯作者	Xiang, Xue-Ping; Fang, Luo
作者单位	1.Univ Chinese Acad Sci, Dept Pharm, Canc Hosp,Chinese Acad Sci, Zhejiang Canc Hosp,Inst Basic Med & Canc IBMC, Hangzhou, Peoples R China 2.Zhejiang Prov Peoples Hosp, Dept Pharm, Hangzhou, Peoples R China 3.Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Pathol, Hangzhou 310009, Peoples R China
推荐引用方式 GB/T 7714	Tong, Ying-Hui,Hu, Xiao-Ping,Xiang, Xue-Ping,et al. High expression of monocarboxylate transporter 4 (MCT 4), but not MCT 1, predicts poor prognosis in patients with non-small cell lung cancer[J]. TRANSLATIONAL CANCER RESEARCH,2021,10.
APA	Tong, Ying-Hui,Hu, Xiao-Ping,Xiang, Xue-Ping,&Fang, Luo.(2021).High expression of monocarboxylate transporter 4 (MCT 4), but not MCT 1, predicts poor prognosis in patients with non-small cell lung cancer.TRANSLATIONAL CANCER RESEARCH,10.
MLA	Tong, Ying-Hui,et al."High expression of monocarboxylate transporter 4 (MCT 4), but not MCT 1, predicts poor prognosis in patients with non-small cell lung cancer".TRANSLATIONAL CANCER RESEARCH 10(2021).